Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers
暂无分享,去创建一个
N. Lee | Min-Jeong Park | Wonkeun Song | Seri Jeong | H. S. Kim | Su Kyung Lee | J. Hyun | Eun-Jung Cho | Jungwon Hyun
[1] Su‐Kyung Lee,et al. Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies , 2022, Annals of Laboratory Medicine.
[2] L. Cosmi,et al. Long-lasting cellular immunity to SARS-CoV-2 following infection or vaccination and implications for booster strategies , 2021, medRxiv.
[3] V. Libri,et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial , 2021, The Lancet.
[4] Susan Hopkins,et al. COV-BOOST: evidence to support rapid booster deployment , 2021, The Lancet.
[5] Scott M Elliott,et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.
[6] Jongmin Lee,et al. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays , 2021, Annals of laboratory medicine.
[7] I. Diamond,et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, Nature Medicine.
[8] N. Lee,et al. Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study , 2021, Journal of clinical microbiology.
[9] M. Hernán,et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.
[10] S. Truelove,et al. A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease , 2021, medRxiv.
[11] K. Peck,et al. Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdOx1 nCoV-19 Vaccine , 2021, Frontiers in Immunology.
[12] N. Andrews,et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK , 2021, medRxiv.
[13] I. Pedraza,et al. T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals , 2021, Cellular & Molecular Immunology.
[14] Michael I. Mandel,et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.
[15] V. Libri,et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.
[16] R. Scheuermann,et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals , 2021, Cell Reports Medicine.
[17] N. Lee,et al. Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers , 2021, Journal of clinical microbiology.
[18] N. Banaei,et al. Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report , 2021, International Journal of Infectious Diseases.
[19] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[20] M. Koopmans,et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients , 2021, Science Immunology.
[21] Zhipeng Yan,et al. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials , 2021, Pharmaceuticals.
[22] P. Klenerman,et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) , 2021, The Lancet.
[23] T. Morrison,et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection , 2021, Journal of Clinical Microbiology.
[24] V. Kulasingam,et al. Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation , 2021, Journal of Clinical Microbiology.
[25] Gavin J. D. Smith,et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients , 2021, Cell Reports.
[26] K. Chu,et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial , 2020, The Lancet Infectious Diseases.
[27] Shyr-Chyr Chen,et al. Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan , 2020, Emerging microbes & infections.
[28] Gerhard Nahler. Observational Study , 2018 .
[29] D. C. Henckel,et al. Case report. , 1995, Journal.